rTMS for Depression: 5 Key Clinical Insights
An evidence synthesis on indication expansion, protocol evolution, and clinical overlap with movement-disorder neuromodulation
One-Minute Takeaway on rTMS for Depression
One-Minute Takeaway
- rTMS for depression carries Strong evidence in treatment-resistant major depression, with a meta-analytic response number-needed-to-treat near 6 and odds of response roughly 3-fold higher than sham across pooled randomized trials.
- Intermittent theta-burst stimulation has demonstrated non-inferiority to standard 10 Hz left dorsolateral prefrontal cortex stimulation, while compressing each session from about 38 minutes to roughly 3 minutes.
- Accelerated, MRI-guided, 5-day protocols (SAINT and SNT) produced remission rates above 50% in early sham-controlled trials, but evidence remains limited by small samples and single-site origin.
- In Parkinson disease, motor-cortex stimulation improves UPDRS motor scores with Class I evidence, whereas prefrontal stimulation for comorbid depression has shown inconsistent benefit.
- FDA clearances have expanded beyond depression to obsessive-compulsive disorder, smoking cessation, and adolescents aged 15 and older, with bipolar depression holding only breakthrough status.
Why rTMS for Depression Matters in Neurology
Major depressive disorder is the leading single cause of years lived with disability worldwide, and roughly a third of treated patients meet criteria for treatment-resistant depression after two or more adequate antidepressant trials. For these patients, options have historically been limited to electroconvulsive therapy, augmentation strategies, or referral for clinical trial enrollment.
Repetitive transcranial magnetic stimulation entered routine US practice in 2008 with FDA clearance for treatment-resistant major depression. The intervening years have produced a dense evidence base on rTMS for depression spanning standard high-frequency protocols, theta-burst variants, deep TMS, and accelerated MRI-guided regimens.
The neurology relevance is twofold. First, neurologists see depression frequently as a comorbidity in Parkinson disease, stroke, multiple sclerosis, epilepsy, and chronic pain, where its treatment intersects with primary disease management. Second, the same neuromodulation infrastructure used for movement-disorder applications, such as motor-cortex stimulation in Parkinson disease, can be redeployed for prefrontal mood targets, creating cross-discipline cost and operational efficiencies.
Evidence Reviewed for rTMS for Depression
This synthesis draws on the dominant systematic reviews and randomized trials shaping current practice on rTMS for depression. The table compares the largest network meta-analysis of antidepressant rTMS, the pivotal iTBS non-inferiority trial, the Stanford accelerated MRI-guided protocols, the European evidence-based guidelines, and two Parkinson disease-specific trials that illuminate target selection.
| Source | Design | Population | Intervention | Primary Outcome | Key Result |
|---|---|---|---|---|---|
| Brunoni 2017 | Network meta-analysis | MDD (acute episode), 81 trials | Multiple rTMS protocols vs sham | Response and remission | All active protocols superior to sham; priming + HF-left ranked highest |
| THREE-D (Blumberger 2018) | Randomized non-inferiority trial | 414 adults with TRD | iTBS vs 10 Hz left DLPFC, 4–6 weeks | HRSD-17 change at endpoint | iTBS non-inferior; adjusted difference 0.103 points |
| SAINT (Cole 2020) | Open-label feasibility | 21 adults with TRD | 5-day accelerated iTBS, fMRI-guided | Remission rate | ~90% remission immediately post-treatment |
| SNT (Cole 2022) | Double-blind RCT | 29 adults with TRD | 5-day SNT vs sham, fMRI-guided iTBS | MADRS change, remission | Active 57% remission vs sham 0% at week 4 |
| Zaidi 2024 | Systematic review & MA | MDD with concurrent antidepressant | rTMS + SSRI/SNRI/other vs sham + drug | Depression response | SSRI co-treatment associated with largest pooled effect |
| Lefaucheur 2020 guidelines | Evidence-based guideline | Multiple neuropsychiatric indications | Recommendation per indication | Level A/B recommendations | Level A for HF-rTMS left DLPFC in unipolar depression |
| Xie 2015 (PD-depression) | Meta-analysis (RCTs) | 312 PD patients with depression | rTMS vs sham or SSRIs | HRSD score change | rTMS superior to sham; comparable to SSRI on mood |
| MASTER-PD (Brys 2016) | 4-arm randomized Class I trial | 61 PD patients with depression | M1, DLPFC, both, or double sham | UPDRS-III and HRSD at 1 month | M1 improved motor; DLPFC did not improve mood vs sham |
| Mendlowitz 2019 | Cost analysis (THREE-D) | Same TRD cohort as THREE-D | iTBS vs 10 Hz rTMS | Cost per remission | iTBS markedly cheaper per remitted patient |
| Zhao 2025 (youth) | Systematic review & MA | 1,295 patients aged 10–25 y | rTMS vs sham | Depression scale change, response | SMD −0.93; NNT ~10 for remission |
Across this evidence base, more than 80 randomized trials and several large systematic reviews provide convergent support for rTMS for depression as an effective option after antidepressant non-response. The protocols differ in pulse number, frequency, target localization method, session count, and duration.
Key Findings on rTMS for Depression
1. Robust Antidepressant Efficacy in Treatment-Resistant Depression
The largest network meta-analysis to date pooled data from 81 randomized trials and found that every active rTMS modality outperformed sham in producing depressive symptom response and remission, with high-frequency left DLPFC stimulation among the most efficacious protocols. An umbrella analysis of 28 prior meta-analyses estimated the pooled odds ratio for response in TRD at 3.27 with a 95% confidence interval of 2.76 to 3.87, and the odds of remission at 2.83 (95% CI 2.33 to 3.45).
European evidence-based guidelines from the Lefaucheur consortium assigned a Level A recommendation, the highest tier signifying definite efficacy, to high-frequency rTMS of the left DLPFC in unipolar depressive episodes. These pooled estimates are consistent with a number-needed-to-treat near 6 for response in TRD samples and place rTMS for depression among the most evidence-supported noninvasive neuromodulation interventions in neuropsychiatry.
2. iTBS Non-Inferiority Shortens Session Time Without Cost to Efficacy
The Canadian THREE-D trial randomized 414 adults with TRD to either standard 37.5-minute 10 Hz left DLPFC stimulation or 3-minute intermittent theta-burst stimulation, delivered daily over 4–6 weeks. HRSD-17 scores improved from baseline 23.5 to 13.4 in the 10 Hz arm and from 23.6 to 13.4 in the iTBS arm.
The adjusted between-group difference was 0.103 points, well within the prespecified non-inferiority margin. Dropout rates and serious adverse events were comparable. Cost analysis of the same cohort found iTBS substantially less expensive per remitted patient, primarily by allowing more patients through the same device per day.
3. Accelerated MRI-Guided Protocols Show Early Signal of Higher Remission
The Stanford Accelerated Intelligent Neuromodulation Therapy protocol delivers 10 iTBS sessions per day for 5 consecutive days, with the target chosen by individual functional connectivity MRI of the DLPFC node most anti-correlated with the subgenual cingulate. The open-label feasibility trial in 21 patients with severe TRD reported remission in approximately 90% within days.
A subsequent 29-patient randomized, double-blind sham-controlled trial of the same approach, rebranded Stanford Neuromodulation Therapy, showed 57.1% remission in the active arm and 0% in the sham arm at week 4. Effect sizes were unusually large for an antidepressant trial, with a Cohen’s d of approximately 1.7.
These findings should be interpreted as preliminary. Sample sizes were small, both pivotal studies emerged from a single research group, and the protocol requires functional MRI infrastructure and dedicated daily sessions that are difficult to scale in community settings.
4. Depression in Parkinson Disease — A Domain of Particular Neurology Relevance
Depression affects an estimated 35–50% of patients with Parkinson disease and contributes substantially to disability and quality-of-life burden. A meta-analysis of 8 randomized trials pooling 312 PD patients found that rTMS reduced Hamilton Depression Rating Scale scores significantly more than sham and produced antidepressant effects comparable to SSRIs on mood endpoints.
The same analysis observed that rTMS in PD patients was associated with improved Unified Parkinson’s Disease Rating Scale and activities of daily living scores, suggesting a dual mood-and-motor benefit. The certainty here is moderate: trials were small, heterogeneous in protocol, and primarily Asian.
5. Target Choice Matters — Motor Cortex Versus Prefrontal Cortex
The MASTER-PD trial randomized 61 PD patients with depression to bilateral M1, left DLPFC, both, or double sham across 10 daily sessions. The trial provided Class I evidence that M1 stimulation produced superior motor improvement compared with sham, while DLPFC stimulation did not improve mood relative to sham at the 1-month endpoint.
This finding contrasts with the broader Parkinson-depression meta-analysis and serves as a useful counterweight. The discordance likely reflects differences in stimulation parameters, target localization precision, and comorbidity profile. For neurologists, the practical lesson is that target choice in PD is symptom-specific: M1 for motor, DLPFC for mood, and the supporting data for the latter remain less consistent than for the former.
Quality & Consistency of the Evidence
Evidence quality varies meaningfully across the indications and protocols that fall under rTMS for depression. The synthesis below maps the dominant claims to their evidence tier.
What the Evidence Does Not Yet Show
Specific Knowledge Gaps
- Long-term durability: The proportion of responders who maintain remission at 6, 12, and 24 months without continuation therapy is not well characterized in pooled randomized data.
- Maintenance schedules: No randomized trial has established an optimal maintenance frequency or duration after an acute course of rTMS for depression.
- Head-to-head versus ECT and esketamine: Direct randomized comparisons against the two other major evidence-based neurostimulation and rapid-acting antidepressant options remain limited.
- Personalized targeting at scale: Whether fMRI-guided individualized DLPFC targets outperform scalp-based heuristics in routine community settings, beyond Stanford’s accelerated trials, is not yet established.
- Predictors of response: Reliable clinical, neuroimaging, or EEG biomarkers of likely response have been proposed but not prospectively validated for routine use.
- Pediatric and adolescent long-term safety: March 2024 FDA clearance extended rTMS for depression to patients aged 15 and older, but long-term cognitive and developmental data in this age range remain sparse.
- Bipolar depression treatment selection: Whether rTMS protocols developed for unipolar TRD are interchangeable for bipolar depression, and at what risk of treatment-emergent mania, is unsettled.
- Cost-effectiveness in neurological populations: Formal economic comparisons of rTMS versus standard pharmacological care for PD-associated depression or post-stroke depression are scarce.
Practical Implications
The following implications reflect what the current evidence base supports for routine practice. They are framed as considerations for discussion with patients and multidisciplinary teams, not as directive prescriptions.
Evidence Supports rTMS After Antidepressant Non-Response
After 1–2 failed adequate antidepressant trials, the cumulative evidence supports considering rTMS for depression before moving to more invasive options. Guideline-level support is strongest for high-frequency left DLPFC stimulation.
iTBS Reduces Chair Time Without Efficacy Loss
For programs deciding between protocols, the iTBS evidence supports choosing the 3-minute regimen when throughput or patient burden is a concern. Cost data from the THREE-D cohort show a lower cost per remission.
Evidence Distinguishes Targets in Parkinson Disease
For PD patients, the evidence base is stronger for M1 stimulation for motor symptoms than for DLPFC stimulation for comorbid depression. Discussing this asymmetry with patients before initiating rTMS for depression in PD reflects current data.
Pre-treatment Screening Mitigates Seizure Risk
The dominant serious safety signal across rTMS protocols is seizure induction, with absolute incidence very low but elevated in patients with epilepsy history, intracranial metal, or proconvulsant medications. Screening before each course aligns with consensus safety guidelines.
Accelerated Protocols Remain Selective
Accelerated MRI-guided protocols such as SAINT and SNT are FDA-cleared for TRD, but the supporting trials are small and single-site. Centers without functional MRI capacity will continue to rely on standard or theta-burst regimens until larger replications are available.
Concurrent Antidepressant Choice Likely Matters
A 2024 systematic review found that SSRI co-treatment was associated with the largest pooled response to concurrent rTMS for depression versus other antidepressant classes. This suggests that current SSRI exposure should be considered, rather than reflexively stopped, when starting rTMS.
Evidence Grade and Bottom Line
Overall Evidence Grade: Strong for TRD response and iTBS non-inferiority; Moderate for PD-associated depression and post-stroke depression; Limited for accelerated MRI-guided protocols and bipolar depression.
The core efficacy claim — that rTMS for depression reduces depressive symptoms more than sham in adults with treatment-resistant unipolar major depression — rests on dozens of randomized trials and converging network meta-analyses. This claim is unlikely to be overturned by future evidence. Claims about specific protocol superiority and about expanded indications are at earlier stages and are more likely to evolve.
Bottom Line
- rTMS for depression remains the most evidence-supported noninvasive neuromodulation option for treatment-resistant major depression, with response odds roughly three-fold higher than sham across pooled randomized data.
- Intermittent theta-burst stimulation offers equivalent efficacy to standard 10 Hz protocols in a fraction of the session time, reshaping operational economics without compromising clinical outcomes.
- Accelerated MRI-guided 5-day protocols show striking remission rates in small randomized trials but await large-scale replication and broader community implementation experience.
- In Parkinson disease and other neurology populations, target choice is symptom-specific and the evidence for prefrontal mood targeting is less consistent than for motor-cortex stimulation; honest disclosure of this asymmetry supports informed consent.
- Long-term durability, optimal maintenance schedules, and head-to-head comparisons against ECT and esketamine remain the central unanswered questions and should anchor patient counselling about expected duration of benefit.
Article Information
Disclaimer
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Lefaucheur JP, Aleman A, Baeken C, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018). Clin Neurophysiol. 2020;131(2):474–528. DOI: 10.1016/j.clinph.2019.11.002
- Brunoni AR, Chaimani A, Moffa AH, et al. Repetitive transcranial magnetic stimulation for the acute treatment of major depressive episodes: a systematic review with network meta-analysis. JAMA Psychiatry. 2017;74(2):143–152. DOI: 10.1001/jamapsychiatry.2016.3644
- Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018;391(10131):1683–1692. DOI: 10.1016/S0140-6736(18)30295-2
- Cole EJ, Stimpson KH, Bentzley BS, et al. Stanford Accelerated Intelligent Neuromodulation Therapy for treatment-resistant depression. Am J Psychiatry. 2020;177(8):716–726. DOI: 10.1176/appi.ajp.2019.19070720
- Cole EJ, Phillips AL, Bentzley BS, et al. Stanford Neuromodulation Therapy (SNT): a double-blind randomized controlled trial. Am J Psychiatry. 2022;179(2):132–141. DOI: 10.1176/appi.ajp.2021.20101429
- Zaidi A, Shami R, Sewell IJ, et al. Antidepressant class and concurrent rTMS outcomes in major depressive disorder: a systematic review and meta-analysis. EClinicalMedicine. 2024;75:102760. DOI: 10.1016/j.eclinm.2024.102760
- Xie CL, Chen J, Wang XD, et al. Repetitive transcranial magnetic stimulation (rTMS) for the treatment of depression in Parkinson disease: a meta-analysis of randomized controlled clinical trials. Neurol Sci. 2015;36(10):1751–1761. DOI: 10.1007/s10072-015-2345-4
- Brys M, Fox MD, Agarwal S, et al. Multifocal repetitive TMS for motor and mood symptoms of Parkinson disease: a randomized trial. Neurology. 2016;87(18):1907–1915. DOI: 10.1212/WNL.0000000000003279
- Mendlowitz AB, Shanbour A, Downar J, et al. Implementation of intermittent theta burst stimulation compared to conventional repetitive transcranial magnetic stimulation in patients with treatment resistant depression: a cost analysis. PLoS One. 2019;14(9):e0222546. DOI: 10.1371/journal.pone.0222546
- Zhao W, Jiang X, Bo Q, et al. Efficacy and safety of repetitive transcranial magnetic stimulation in youth with depression: a systematic review and meta-analysis of randomized sham-controlled trials. World J Pediatr. 2025. DOI: 10.1007/s12519-025-00983-7